Arcinova - A Quotient Sciences Company published a blog by Michael Blackburn exploring how advanced LC-MS approaches can help overcome bioanalytical challenges for insulin analogues and large peptides.

Arcinova, A Quotient Sciences Company, is dedicated to providing innovative contract research, development, and manufacturing services. We offer a comprehensive range of integrated specialist services for early stage drug development, underpinned by strong industry knowledge and scientific expertise. Our mission is to bring science, innovation, and collaboration together to overcome the barriers in drug development. We empower emerging biotechs and large pharma alike to bring life-changing therapies to patients faster, through an efficient, effective approach focused on quality, science, and innovation. Our vision is to advance progress through science, delivering solutions that make a measurable difference. We look ahead with purpose, driven to shape a smarter, more resilient future for all.